Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma
Nivolumab with or without ipilimumab shows similar objective response rates in patients with recurrent or metastatic Merkel cell carcinoma.
The study indicates that adding ipilimumab to nivolumab does not improve efficacy but increases severe adverse events, suggesting single‑agent nivolumab remains the preferred first‑line immune checkpoint blockade for Merkel cell carcinoma.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies